April 11 marks International Parkinson's Disease Day. Parkinson's disease (PD) is a common neurodegenerative disorder, often termed the "Silent Chronic Disease," quietly affecting an increasing number of lives. Data indicate that by 2040, the total number of patients is expected to exceed 12 million, making it one of the fastest-growing neurological diseases globally. In China, with the acceleration of population aging, the number of PD patients is rising rapidly. Currently, approximately 4 million patients in China are battling this disease.

On the occasion of International Parkinson's Disease Day, Ms. Shen, the first Chinese recipient of Bio, and Dr. Li Dianyou, Director of Functional Neurosurgery at Ruijin Hospital, meticulously planned the surgical approach based on preoperative imaging for the first patient. Dr. Li's team then successfully performed the minimally invasive "Autologous iPSC-Derived Cell Therapy UX-DA001 for Parkinson's Disease" procedure. This milestone marked the official launch of China's first registered clinical-grade autologous iPSC-derived cell therapy for PD.

The UX-DA001 injection, independently developed by According to Dr. Li Dianyou, the transplanted cells will mature over 36 months, integrating with existing neural networks to dynamically regulate dopamine release under physiological conditions. Compared to traditional drugs, this "cell replacement" therapy holds potential for functional cure.

DA001 is  UniXellBio's team to advance this cutting-edge medical approach, offering tangible hope to patients and bridging innovative science with public health.